Evaluation of 64Cu-based radiopharmaceuticals that target Aβ peptide aggregates as diagnostic tools for Alzheimer’s disease

Authors

Nilantha Bandara, Washington University School of Medicine in St. Louis
Anuj K. Sharma, Washington University in St. Louis
Stephanie Krieger, Washington University School of Medicine in St. Louis
Jason W. Schultz, Washington University in St. Louis
Byung Hee Han, Kirksville College of Osteopathic Medicine
Buck E. Rogers, Washington University School of Medicine in St. Louis
Liviu M. Mirica, Washington University School of Medicine in St. Louis

Journal

Journal of the American Chemical Society

Publication Date

2017

Volume

139

Issue

36

Inclusive Pages

12550-12558

Document Type

Open Access Publication

DOI

10.1021/jacs.7b05937

Rights and Permissions

Bandara N, Sharma AK, Krieger S, Schultz JW, Han BH, Rogers BE, Mirica LM (2017) Evaluation of 64Cu-Based Radiopharmaceuticals that Target Aβ Peptide Aggregates as Diagnostic Tools for Alzheimer’s Disease. J. Am. Chem. Soc. 139(36):12550-12558. DOI: 10.1021/jacs.7b05937 This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

Recommended Citation

Bandara, Nilantha; Sharma, Anuj K.; Krieger, Stephanie; Schultz, Jason W.; Han, Byung Hee; Rogers, Buck E.; and Mirica, Liviu M., "Evaluation of 64Cu-based radiopharmaceuticals that target Aβ peptide aggregates as diagnostic tools for Alzheimer’s disease." Journal of the American Chemical Society. 139, 36. 12550-12558. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/6924